11 results
6-K
EX-99.1
MPSYF
MorphoSys AG
20 Mar 24
Current report (foreign)
4:12pm
., and Asian markets. The proprietary development programs form the basis for the Company’s success and are protected by numerous patent families
6-K
EX-99.1
MPSYF
MorphoSys AG
13 Mar 24
Current report (foreign)
4:08pm
antibody library, patents have been granted in all major territories, including in the European, U.S., and Asian markets. The proprietary development
6-K
EX-99.2
MPSYF
MorphoSys AG
11 Dec 23
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
11:26am
)85 (39.7) / 129 (60.3)Female / maleSex — n (%) 163 (75.5) / 42 (19.4) / 0160 (74.8) / 35 (16.4) / 2 (0.9)White / Asian / Black Race — n (%) 01 (0.5
6-K
EX-99.1
MPSYF
MorphoSys AG
23 Mar 22
Current report (foreign)
4:15pm
by numerous patent families. For our Ylanthia antibody library, patents have been granted in all major territories, including Europe, the U.S. and Asian
6-K
EX-99.1
984t 6hkioju555m
16 Mar 22
2021 Annual Report A nn ua l R ep or t 20 21
4:55pm
6-K
EX-99.1
zsk gn501m84hn
23 Mar 21
Current report (foreign)
3:53pm
6-K
EX-99.1
j80x6lrg4lx1yo
22 Mar 21
Current report (foreign)
12:42pm
6-K
EX-99.1
h3ttjprsd
21 Mar 19
Current report (foreign)
6:14am
6-K
EX-99.1
vyedr
15 Mar 19
2018 annual report Morphosys Engineering the Medicines of Tomorrow
6:27am
20-F
m8612qw5dlmi6b9w
13 Mar 19
Annual report (foreign)
5:13pm
- Prev
- 1
- Next